Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2021-07-08 16:43 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,814
-3,646 vol $9.00 each |
0 | |
Filed 2021-07-08 16:42 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-07-08 16:40 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
81,427 | |
Filed 2021-07-02 13:18 Tx date 2021-07-01 |
$TRIL
Trillium Therapeutics Inc. |
Mackey, Catherine Jane
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$649,900
+67,000 vol $9.70 each |
67,000 | |
Filed 2021-06-30 13:15 Tx date 2021-06-30 |
$TRIL
Trillium Therapeutics Inc. |
Mackey, Catherine Jane
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-06-08 17:49 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,152.42
-3,646 vol $8.27 each |
0 | |
Filed 2021-06-08 17:48 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-06-08 17:45 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
85,073 | |
Filed 2021-05-18 10:52 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+133,555 vol |
408,555 | |
Filed 2021-05-18 10:50 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-133,555 vol |
1,550,945 | |
Filed 2021-05-13 18:07 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-219,880.4958
-23,802 vol $9.24 each |
0 | |
Filed 2021-05-13 18:06 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$9,044
+23,802 vol $0.38 each |
23,802 | |
Filed 2021-05-13 18:04 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-9,044.76
-23,802 vol $0.38 each |
1,684,500 | |
Filed 2021-05-13 18:03 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-176,654.2366
-19,198 vol $9.20 each |
0 | |
Filed 2021-05-13 18:02 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$7,295
+19,198 vol $0.38 each |
19,198 | |
Filed 2021-05-13 18:00 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-7,295.24
-19,198 vol $0.38 each |
1,708,302 | |
Filed 2021-05-13 17:59 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-805,148.75
-87,500 vol $9.20 each |
0 | |
Filed 2021-05-13 17:57 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$47,250
+87,500 vol $0.54 each |
87,500 | |
Filed 2021-05-13 17:56 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-05-13 17:53 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-47,250
-87,500 vol $0.54 each |
1,727,500 | |
Filed 2021-05-10 17:20 Tx date 2021-05-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-33,907.80
-3,646 vol $9.30 each |
0 | |
Filed 2021-05-10 17:19 Tx date 2021-05-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-05-10 17:17 Tx date 2021-05-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
88,719 | |
Filed 2021-05-04 17:37 Tx date 2021-05-03 |
$TRIL
Trillium Therapeutics Inc. |
Looker, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,806,900
+190,000 vol $9.51 each |
190,000 | |
Filed 2021-05-04 17:32 Tx date 2021-04-26 |
$TRIL
Trillium Therapeutics Inc. |
Looker, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-05-04 09:05 Tx date 2021-05-03 |
$TRIL
Trillium Therapeutics Inc. |
Myers, Scott Dunseth
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$637,170
+67,000 vol $9.51 each |
67,000 | |
Filed 2021-04-28 16:52 Tx date 2021-04-28 |
$TRIL
Trillium Therapeutics Inc. |
Myers, Scott Dunseth
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-04-09 17:11 Tx date 2021-04-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-39,449.72
-3,646 vol $10.82 each |
0 | |
Filed 2021-04-09 17:10 Tx date 2021-04-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-04-09 17:09 Tx date 2021-04-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
92,365 | |
Filed 2021-04-09 15:16 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,878.36
-2,604 vol $11.09 each |
0 | |
Filed 2021-04-09 15:15 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$11,014
+2,604 vol $4.23 each |
2,604 | |
Filed 2021-04-09 15:13 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-11,014.92
-2,604 vol $4.23 each |
68,929 | |
Filed 2021-04-09 15:11 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,031.72
-2,708 vol $11.09 each |
0 | |
Filed 2021-04-09 15:10 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,029
+2,708 vol $0.38 each |
2,708 | |
Filed 2021-04-09 15:08 Tx date 2021-04-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,029.04
-2,708 vol $0.38 each |
71,533 | |
Filed 2021-03-15 14:36 Tx date 2021-03-12 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-34,916.49
-2,917 vol $11.97 each |
0 | |
Filed 2021-03-15 14:34 Tx date 2021-03-12 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$12,338
+2,917 vol $4.23 each |
2,917 | |
Filed 2021-03-15 14:31 Tx date 2021-03-12 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-12,338.91
-2,917 vol $4.23 each |
96,011 | |
Filed 2021-03-12 15:43 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,852.32
-2,604 vol $11.08 each |
0 | |
Filed 2021-03-12 15:42 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$11,014
+2,604 vol $4.23 each |
2,604 | |
Filed 2021-03-12 15:37 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-11,014.92
-2,604 vol $4.23 each |
74,241 | |
Filed 2021-03-12 15:34 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,004.64
-2,708 vol $11.08 each |
0 | |
Filed 2021-03-12 15:33 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,029
+2,708 vol $0.38 each |
2,708 | |
Filed 2021-03-12 15:29 Tx date 2021-03-10 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,029.04
-2,708 vol $0.38 each |
76,845 | |
Filed 2021-03-10 13:47 Tx date 2021-03-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-36,861.06
-3,646 vol $10.11 each |
0 | |
Filed 2021-03-10 13:47 Tx date 2021-03-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-03-10 13:44 Tx date 2021-03-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
98,928 | |
Filed 2021-02-10 20:38 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,248.416
-584 vol $14.12 each |
0 | |
Filed 2021-02-10 20:37 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$7,136
+584 vol $12.22 each |
584 | |
Filed 2021-02-10 20:36 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-7,136.48
-584 vol $12.22 each |
102,574 | |
Filed 2021-02-10 20:35 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-36,900.05
-2,917 vol $12.65 each |
0 | |
Filed 2021-02-10 20:34 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$12,338
+2,917 vol $4.23 each |
2,917 | |
Filed 2021-02-10 20:33 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-12,338.91
-2,917 vol $4.23 each |
103,158 | |
Filed 2021-02-10 20:31 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-46,121.90
-3,646 vol $12.65 each |
0 | |
Filed 2021-02-10 20:30 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-02-10 20:29 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
106,075 | |
Filed 2021-02-10 20:27 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,200.392
-508 vol $14.17 each |
0 | |
Filed 2021-02-10 20:25 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$6,207
+508 vol $12.22 each |
508 | |
Filed 2021-02-10 20:24 Tx date 2021-02-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-6,207.76
-508 vol $12.22 each |
79,553 | |
Filed 2021-02-10 20:14 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,940.60
-2,604 vol $12.65 each |
0 | |
Filed 2021-02-10 20:13 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$11,014
+2,604 vol $4.23 each |
2,604 | |
Filed 2021-02-10 20:12 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-11,014.92
-2,604 vol $4.23 each |
80,061 | |
Filed 2021-02-10 20:07 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-34,256.20
-2,708 vol $12.65 each |
0 | |
Filed 2021-02-10 20:05 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,029
+2,708 vol $0.38 each |
2,708 | |
Filed 2021-02-10 20:00 Tx date 2021-02-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,029.04
-2,708 vol $0.38 each |
82,665 | |
Filed 2021-01-15 17:31 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-294,278.9328
-19,581 vol $15.03 each |
0 | |
Filed 2021-01-15 17:30 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$10,573
+19,581 vol $0.54 each |
19,581 | |
Filed 2021-01-15 17:29 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-10,573.74
-19,581 vol $0.54 each |
275,000 | |
Filed 2021-01-15 17:28 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,507.7209
-5,419 vol $15.04 each |
0 | |
Filed 2021-01-15 17:27 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$2,926
+5,419 vol $0.54 each |
5,419 | |
Filed 2021-01-15 17:21 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-2,926.26
-5,419 vol $0.54 each |
294,581 | |
Filed 2021-01-12 19:42 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,878.6688
-584 vol $15.20 each |
0 | |
Filed 2021-01-12 19:41 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$7,136
+584 vol $12.22 each |
584 | |
Filed 2021-01-12 19:40 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-7,136.48
-584 vol $12.22 each |
109,721 | |
Filed 2021-01-12 19:39 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-45,230.4186
-2,917 vol $15.51 each |
0 | |
Filed 2021-01-12 19:38 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$12,338
+2,917 vol $4.23 each |
2,917 | |
Filed 2021-01-12 19:37 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-12,338.91
-2,917 vol $4.23 each |
110,305 | |
Filed 2021-01-12 19:36 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-88,575.20
-5,600 vol $15.82 each |
0 | |
Filed 2021-01-12 19:32 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$78,288
+5,600 vol $13.98 each |
5,600 | |
Filed 2021-01-12 19:31 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-78,288
-5,600 vol $13.98 each |
113,222 | |
Filed 2021-01-12 19:29 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,725.3084
-508 vol $15.21 each |
0 | |
Filed 2021-01-12 19:28 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$6,207
+508 vol $12.22 each |
508 | |
Filed 2021-01-12 19:26 Tx date 2021-01-11 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-6,207.76
-508 vol $12.22 each |
85,373 | |
Filed 2021-01-12 19:25 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-40,364.604
-2,604 vol $15.50 each |
0 | |
Filed 2021-01-12 19:22 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$11,014
+2,604 vol $4.23 each |
2,604 | |
Filed 2021-01-12 19:21 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-11,014.92
-2,604 vol $4.23 each |
85,881 | |
Filed 2021-01-12 16:58 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-53,782.146
-3,646 vol $14.75 each |
0 | |
Filed 2021-01-12 16:56 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
Filed 2021-01-12 16:55 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
118,822 | |
Filed 2021-01-12 16:41 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-39,842.804
-2,708 vol $14.71 each |
0 | |
Filed 2021-01-12 16:38 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,029
+2,708 vol $0.38 each |
2,708 | |
Filed 2021-01-12 16:35 Tx date 2021-01-07 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,029.04
-2,708 vol $0.38 each |
88,485 | |
Filed 2021-01-12 12:21 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-134,270.9865
-8,505 vol $15.79 each |
0 | |
Filed 2021-01-12 12:19 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$78,246
+8,505 vol $9.20 each |
8,505 | |
Filed 2021-01-12 12:12 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-78,246
-8,505 vol $9.20 each |
173,492 | |
Filed 2021-01-04 13:45 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-307,104.684
-21,621 vol $14.20 each |
0 | |
Filed 2021-01-04 13:43 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$264,208
+21,621 vol $12.22 each |
21,621 | |
Filed 2021-01-04 13:42 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-264,208.62
-21,621 vol $12.22 each |
122,468 | |
Filed 2021-01-04 13:39 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-562,638.384
-38,808 vol $14.50 each |
0 | |
Filed 2021-01-04 13:38 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$542,535
+38,808 vol $13.98 each |
38,808 | |
Filed 2021-01-04 13:37 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-272,562.40
-18,800 vol $14.50 each |
0 | |
Filed 2021-01-04 13:37 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$229,736
+18,800 vol $12.22 each |
18,800 | |
Filed 2021-01-04 13:35 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-542,535.84
-38,808 vol $13.98 each |
91,193 | |
Filed 2021-01-04 13:34 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-229,736
-18,800 vol $12.22 each |
130,001 | |
Filed 2021-01-04 13:32 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-398,751.45
-26,970 vol $14.79 each |
0 | |
Filed 2021-01-04 13:30 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$224,929
+26,970 vol $8.34 each |
26,970 | |
Filed 2021-01-04 13:29 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-62,836.25
-4,250 vol $14.79 each |
0 | |
Filed 2021-01-04 13:28 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$31,875
+4,250 vol $7.50 each |
4,250 | |
Filed 2021-01-04 13:26 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-224,929.80
-26,970 vol $8.34 each |
181,997 | |
Filed 2021-01-04 13:24 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-31,875
-4,250 vol $7.50 each |
208,967 | |
Filed 2020-12-31 16:42 Tx date 2020-11-12 |
$TRIL
Trillium Therapeutics Inc. |
Bruns, Ingmar
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+400,000 vol |
400,000 | |
Filed 2020-12-31 16:40 Tx date 2020-11-12 |
$TRIL
Trillium Therapeutics Inc. |
Harrison, Rosemary
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+180,000 vol |
180,000 | |
Filed 2020-12-28 22:14 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Walker, Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
40,000 | |
Filed 2020-12-28 22:13 Tx date 2020-02-06 |
$TRIL
Trillium Therapeutics Inc. |
Walker, Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-28 17:06 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$518,234 | |
Filed 2020-12-28 17:05 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:58 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$498,294 | |
Filed 2020-12-28 16:57 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:43 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
46,667 | |
Filed 2020-12-28 16:42 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
||
Filed 2020-12-28 16:37 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+140,000 vol |
247,895 | |
Filed 2020-12-28 16:34 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+180,000 vol |
287,893 | |
Filed 2020-12-28 16:32 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
1,815,000 | |
Filed 2020-12-28 16:31 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
||
Filed 2020-12-28 16:30 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
386,795 | |
Filed 2020-12-28 16:28 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
||
Filed 2020-12-28 16:25 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:24 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
40,000 | |
Filed 2020-12-28 16:23 Tx date 2017-09-13 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-28 16:22 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:22 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$518,234 | |
Filed 2020-12-28 16:20 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
116,667 | |
Filed 2020-12-28 16:16 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$1,974 vol $12.03 each |
$463,993 | |
Filed 2020-12-28 16:14 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
+1,974 vol |
||
Filed 2020-12-28 16:11 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$539,025 | |
Filed 2020-12-28 16:05 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
46,667 | |
Filed 2020-12-28 16:02 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
+1,974 vol |
||
Filed 2020-12-28 15:50 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
||
Filed 2020-12-28 15:50 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
46,667 | |
Filed 2020-12-18 21:41 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-884,115
-75,000 vol $11.79 each |
0 | |
Filed 2020-12-18 21:40 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$28,500
+75,000 vol $0.38 each |
75,000 | |
Filed 2020-12-18 21:39 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-414,143.0424
-35,132 vol $11.79 each |
0 | |
Filed 2020-12-18 21:39 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$18,971
+35,132 vol $0.54 each |
35,132 | |
Filed 2020-12-18 21:31 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-28,500
-75,000 vol $0.38 each |
300,000 | |
Filed 2020-12-18 21:30 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-18,971.28
-35,132 vol $0.54 each |
375,000 | |
Filed 2020-12-18 21:29 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,857,429.9294
-161,094 vol $11.53 each |
0 | |
Filed 2020-12-18 21:28 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$86,990
+161,094 vol $0.54 each |
161,094 | |
Filed 2020-12-18 21:27 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-86,990.76
-161,094 vol $0.54 each |
410,132 | |
Filed 2020-12-18 21:26 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-335,289.035
-28,774 vol $11.65 each |
0 | |
Filed 2020-12-18 21:25 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$15,537
+28,774 vol $0.54 each |
28,774 | |
Filed 2020-12-18 21:23 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-15,537.96
-28,774 vol $0.54 each |
571,226 | |
Filed 2020-12-18 21:22 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,325,262.9708
-114,007 vol $11.62 each |
0 | |
Filed 2020-12-18 21:21 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$61,563
+114,007 vol $0.54 each |
114,007 | |
Filed 2020-12-18 21:20 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-61,563.78
-114,007 vol $0.54 each |
600,000 | |
Filed 2020-12-18 21:18 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-264,489.7332
-21,693 vol $12.19 each |
0 | |
Filed 2020-12-18 21:17 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$8,243
+21,693 vol $0.38 each |
21,693 | |
Filed 2020-12-18 21:16 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-8,243.34
-21,693 vol $0.38 each |
144,089 | |
Filed 2020-12-18 21:15 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-304,694.6398
-25,702 vol $11.85 each |
0 | |
Filed 2020-12-18 21:14 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$9,766
+25,702 vol $0.38 each |
25,702 | |
Filed 2020-12-18 21:13 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-9,766.76
-25,702 vol $0.38 each |
165,782 | |
Filed 2020-12-18 21:12 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-802,363.3418
-67,682 vol $11.85 each |
0 | |
Filed 2020-12-18 21:11 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$52,115
+67,682 vol $0.77 each |
67,682 | |
Filed 2020-12-18 21:07 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-52,115.14
-67,682 vol $0.77 each |
191,484 | |
Filed 2020-12-18 21:06 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-796,296.501
-69,069 vol $11.53 each |
0 | |
Filed 2020-12-18 21:05 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$53,183
+69,069 vol $0.77 each |
69,069 | |
Filed 2020-12-18 21:04 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-53,183.13
-69,069 vol $0.77 each |
259,166 | |
Filed 2020-12-18 21:03 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-154,085.87
-13,249 vol $11.63 each |
0 | |
Filed 2020-12-18 21:02 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$10,201
+13,249 vol $0.77 each |
13,249 | |
Filed 2020-12-18 21:01 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-10,201.73
-13,249 vol $0.77 each |
328,235 | |
Filed 2020-12-18 20:58 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-672,609.42
-57,834 vol $11.63 each |
0 | |
Filed 2020-12-18 20:57 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$244,637
+57,834 vol $4.23 each |
57,834 | |
Filed 2020-12-18 20:55 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-244,637.82
-57,834 vol $4.23 each |
341,484 | |
Filed 2020-12-18 20:51 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-50,361.65
-4,250 vol $11.85 each |
0 | |
Filed 2020-12-18 20:49 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$31,875
+4,250 vol $7.50 each |
4,250 | |
Filed 2020-12-18 20:48 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-239,674.0548
-20,226 vol $11.85 each |
0 | |
Filed 2020-12-18 20:47 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$168,684
+20,226 vol $8.34 each |
20,226 | |
Filed 2020-12-18 20:46 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-164,131.5798
-13,851 vol $11.85 each |
0 | |
Filed 2020-12-18 20:43 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$127,429
+13,851 vol $9.20 each |
13,851 | |
Filed 2020-12-18 20:42 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-309,149.4322
-26,089 vol $11.85 each |
0 | |
Filed 2020-12-18 20:40 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$270,021
+26,089 vol $10.35 each |
26,089 | |
Filed 2020-12-18 20:39 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-199,977.2248
-16,876 vol $11.85 each |
0 | |
Filed 2020-12-18 20:38 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$71,385
+16,876 vol $4.23 each |
16,876 | |
Filed 2020-12-18 20:36 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-556,020.612
-48,228 vol $11.53 each |
0 | |
Filed 2020-12-18 20:36 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$204,004
+48,228 vol $4.23 each |
48,228 | |
Filed 2020-12-18 20:33 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-163,377.459
-14,171 vol $11.53 each |
0 | |
Filed 2020-12-18 20:31 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$5,384
+14,171 vol $0.38 each |
14,171 | |
Filed 2020-12-18 20:29 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-244,660.31
-21,037 vol $11.63 each |
0 | |
Filed 2020-12-18 20:28 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$7,994
+21,037 vol $0.38 each |
21,037 | |
Filed 2020-12-18 20:27 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-501,159.96
-43,092 vol $11.63 each |
0 | |
Filed 2020-12-18 20:26 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$33,180
+43,092 vol $0.77 each |
43,092 | |
Filed 2020-12-18 20:24 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-31,875
-4,250 vol $7.50 each |
148,801 | |
Filed 2020-12-18 20:16 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-168,684.84
-20,226 vol $8.34 each |
153,051 | |
Filed 2020-12-18 20:16 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-127,429.20
-13,851 vol $9.20 each |
173,277 | |
Filed 2020-12-18 20:14 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-270,021.15
-26,089 vol $10.35 each |
187,128 | |
Filed 2020-12-18 20:13 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-71,385.48
-16,876 vol $4.23 each |
213,217 | |
Filed 2020-12-18 20:12 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-204,004.44
-48,228 vol $4.23 each |
230,093 | |
Filed 2020-12-18 20:11 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-5,384.98
-14,171 vol $0.38 each |
278,321 | |
Filed 2020-12-18 20:10 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-7,994.06
-21,037 vol $0.38 each |
292,492 | |
Filed 2020-12-18 20:09 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
52 - Expiration of options
|
$-33,180.84
-43,092 vol $0.77 each |
313,529 | |
Filed 2020-12-18 20:00 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-827,940.5888
-65,104 vol $12.72 each |
0 | |
Filed 2020-12-18 19:59 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$275,389
+65,104 vol $4.23 each |
65,104 | |
Filed 2020-12-18 19:58 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-160,186.382
-14,162 vol $11.31 each |
0 | |
Filed 2020-12-18 19:57 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$5,381
+14,162 vol $0.38 each |
14,162 | |
Filed 2020-12-18 19:56 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-244,764.98
-21,046 vol $11.63 each |
0 | |
Filed 2020-12-18 19:55 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$7,997
+21,046 vol $0.38 each |
21,046 | |
Filed 2020-12-18 19:53 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-501,159.96
-43,092 vol $11.63 each |
0 | |
Filed 2020-12-18 19:52 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$33,180
+43,092 vol $0.77 each |
43,092 | |
Filed 2020-12-18 19:51 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-275,389.92
-65,104 vol $4.23 each |
213,217 | |
Filed 2020-12-18 19:50 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-5,381.56
-14,162 vol $0.38 each |
278,321 | |
Filed 2020-12-18 19:49 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-7,997.48
-21,046 vol $0.38 each |
292,483 | |
Filed 2020-12-18 19:47 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-33,180.84
-43,092 vol $0.77 each |
313,529 | |
Filed 2020-12-18 19:41 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,195,461.372
-185,993 vol $11.80 each |
0 | |
Filed 2020-12-18 19:40 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$100,436
+185,993 vol $0.54 each |
185,993 | |
Filed 2020-12-18 19:38 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 19:37 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-100,436.22
-185,993 vol $0.54 each |
714,007 | |
Filed 2020-12-18 19:36 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-177,135.0736
-15,082 vol $11.74 each |
0 | |
Filed 2020-12-18 19:34 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$63,796
+15,082 vol $4.23 each |
15,082 | |
Filed 2020-12-18 19:33 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-63,796.86
-15,082 vol $4.23 each |
399,318 | |
Filed 2020-12-18 19:32 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-99,842.5448
-8,501 vol $11.74 each |
0 | |
Filed 2020-12-18 19:31 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$63,757
+8,501 vol $7.50 each |
8,501 | |
Filed 2020-12-18 19:30 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-63,757.50
-8,501 vol $7.50 each |
414,400 | |
Filed 2020-12-18 19:29 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-395,952.4424
-33,713 vol $11.74 each |
0 | |
Filed 2020-12-18 19:28 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$281,166
+33,713 vol $8.34 each |
33,713 | |
Filed 2020-12-18 19:27 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-281,166.42
-33,713 vol $8.34 each |
422,901 | |
Filed 2020-12-18 19:26 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-245,595.5128
-20,911 vol $11.74 each |
0 | |
Filed 2020-12-18 19:25 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$192,381
+20,911 vol $9.20 each |
20,911 | |
Filed 2020-12-18 19:23 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-192,381.20
-20,911 vol $9.20 each |
456,614 | |
Filed 2020-12-18 19:21 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-494,056.7568
-42,066 vol $11.74 each |
0 | |
Filed 2020-12-18 19:20 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$435,383
+42,066 vol $10.35 each |
42,066 | |
Filed 2020-12-18 19:19 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 19:18 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-435,383.10
-42,066 vol $10.35 each |
477,525 | |
Filed 2020-12-18 19:15 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,255,613.0784
-106,908 vol $11.74 each |
0 | |
Filed 2020-12-18 19:13 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$82,319
+106,908 vol $0.77 each |
106,908 | |
Filed 2020-12-18 19:11 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 19:10 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-82,319.16
-106,908 vol $0.77 each |
356,621 | |
Filed 2020-12-18 19:06 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,255,613.0784
-106,908 vol $11.74 each |
0 | |
Filed 2020-12-18 19:05 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$82,319
+106,908 vol $0.77 each |
106,908 | |
Filed 2020-12-18 19:03 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 18:42 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+275,833 vol |
275,833 | |
Filed 2020-12-18 18:40 Tx date 2018-06-11 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 18:21 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-82,319.16
-106,908 vol $0.77 each |
356,621 | |
Filed 2020-12-18 18:12 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-275,833 vol |
379,167 | |
Filed 2020-12-18 18:09 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+900,000 vol |
900,000 | |
Filed 2020-12-18 18:07 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 18:06 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
1,215,000 | |
Filed 2020-12-18 18:04 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+519,591 vol |
519,591 | |
Filed 2020-12-18 18:01 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 18:00 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-519,591 vol |
136,795 | |
Filed 2020-12-18 17:58 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+463,529 vol |
463,529 | |
Filed 2020-12-18 17:57 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:56 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
107,895 | |
Filed 2020-12-18 17:54 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
||
Filed 2020-12-18 17:54 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:53 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-519,591 vol |
||
Filed 2020-12-18 17:53 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:52 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
-463,529 vol |
||
Filed 2020-12-18 17:52 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+463,529 vol |
463,529 | |
Filed 2020-12-18 17:42 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:40 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
107,893 | |
Filed 2020-12-18 17:34 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:33 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
||
Filed 2020-12-18 17:27 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:25 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
||
Filed 2020-12-18 17:22 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:21 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-519,591 vol |
||
Filed 2020-12-18 17:19 Tx date 2013-04-09 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:18 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
-463,529 vol |
||
Filed 2020-12-18 16:48 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
463,529 | ||
Filed 2020-12-18 16:48 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 16:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
||
Filed 2020-12-18 16:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
107,893 | |
Filed 2020-11-17 10:44 Tx date 2020-11-15 |
$TRIL
Trillium Therapeutics Inc. |
Pucci, Paolo
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,038,500
+67,000 vol $15.50 each |
67,000 | |
Filed 2020-11-16 10:25 Tx date 2020-11-12 |
$TRIL
Trillium Therapeutics Inc. |
Pucci, Paolo
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-11-09 10:32 Tx date 2020-11-05 |
$TRIL
Trillium Therapeutics Inc. |
Harrison, Rosemary
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
75 | ||
Filed 2020-11-09 08:39 Tx date 2020-11-05 |
$TRIL
Trillium Therapeutics Inc. |
Harrison, Rosemary
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-11-05 11:15 Tx date 2020-11-01 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$249,000
+20,000 vol $12.45 each |
76,667 | |
Filed 2020-11-05 11:13 Tx date 2020-11-01 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$622,500
+50,000 vol $12.45 each |
56,667 | |
Filed 2020-11-04 12:26 Tx date 2020-11-02 |
$TRIL
Trillium Therapeutics Inc. |
Bruns, Ingmar
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-09-18 15:17 Tx date 2020-09-17 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Michael, Kamarck
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$989,590
+67,000 vol $14.77 each |
67,000 | |
Filed 2020-09-18 15:10 Tx date 2020-09-17 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Michael, Kamarck
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-05-08 11:50 Tx date 2020-05-06 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$13,737 vol $4.87 each |
$509,257 | |
Filed 2020-05-08 11:47 Tx date 2020-05-06 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$13,737 vol $4.87 each |
$515,154 | |
Filed 2020-01-02 16:52 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$14,792 vol $1.16 each |
$494,346 | |
Filed 2020-01-02 16:50 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$16,205 vol $1.16 each |
$514,286 | |
Filed 2020-01-02 16:48 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$13,965 vol $1.16 each |
$501,417 | |
Filed 2020-01-02 16:46 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$12,570 vol $1.16 each |
$495,520 | |
Filed 2020-01-02 16:43 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$19,560 vol $1.16 each |
$535,077 | |
Filed 2019-11-12 10:45 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$119,700
+315,000 vol $0.38 each |
2,115,000 | |
Filed 2019-11-12 10:43 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$89,300
+235,000 vol $0.38 each |
655,000 | |
Filed 2019-11-12 10:42 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$66,500
+175,000 vol $0.38 each |
656,386 | |
Filed 2019-11-12 10:40 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$49,400
+130,000 vol $0.38 each |
571,424 | |
Filed 2019-11-12 10:38 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$49,400
+130,000 vol $0.38 each |
571,422 | |
Filed 2019-11-11 14:59 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$482,950 | |
Filed 2019-11-11 14:57 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$479,554 | |
Filed 2019-11-11 14:55 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$498,081 | |
Filed 2019-11-11 14:54 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$487,452 | |
Filed 2019-11-11 14:52 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$113,568 vol $0.36 each |
$462,019 | |
Filed 2019-11-11 14:46 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$515,517 | |
Filed 2019-10-02 15:33 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$39,154 vol $0.4467 each |
$131,221 | |
Filed 2019-10-02 15:31 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$42,895 vol $0.4467 each |
$149,748 | |
Filed 2019-10-02 15:30 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$36,967 vol $0.4467 each |
$139,119 | |
Filed 2019-10-02 15:15 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$51,775 vol $0.4467 each |
$167,184 | |
Filed 2019-10-02 15:10 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$33,273 vol $0.4467 each |
$134,617 | |
Filed 2019-09-27 15:42 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$972,000
+1,800,000 vol $0.54 each |
1,800,000 | |
Filed 2019-09-27 09:49 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-07-03 16:44 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$43,250 vol $0.4358 each |
$348,451 | |
Filed 2019-07-03 16:28 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$228,000 vol $0.77 each |
$305,201 | |
Filed 2019-07-03 14:06 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$41,425 vol $0.4358 each |
$92,067 | |
Filed 2019-07-03 14:04 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$42,531 vol $0.4358 each |
$106,853 | |
Filed 2019-07-03 14:02 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$39,114 vol $0.4358 each |
$102,152 | |
Filed 2019-07-03 14:00 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$49,286 vol $0.4358 each |
$115,409 | |
Filed 2019-07-03 13:57 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$32,161 vol $0.4358 each |
$101,344 | |
Filed 2019-07-03 13:52 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$43,250 vol $0.4358 each |
||
Filed 2019-07-03 13:52 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$43,250 vol $0.4358 each |
$120,451 | |
Filed 2019-05-27 12:54 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
441,422 | |
Filed 2019-05-27 12:51 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
481,386 | |
Filed 2019-05-27 12:42 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
420,000 | |
Filed 2019-05-27 12:21 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
441,424 | |
Filed 2019-04-05 10:14 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$19,614 vol $0.92 each |
$50,642 | |
Filed 2019-04-05 10:12 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$18,531 vol $0.92 each |
$63,038 | |
Filed 2019-04-05 10:09 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$19,815 vol $0.92 each |
$64,322 | |
Filed 2019-04-05 10:06 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$21,616 vol $0.92 each |
$66,123 | |
Filed 2019-04-05 10:02 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$23,177 vol $0.92 each |
$77,201 | |
Filed 2019-04-05 09:58 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$24,676 vol $0.92 each |
$69,183 | |
Filed 2018-11-13 Tx date 2018-07-03 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,580,000
+200,000 vol $7.90 each |
200,000 | |
Filed 2018-11-13 Tx date 2018-06-11 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-13 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Shou, Yaping
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$296,100
+70,000 vol $4.23 each |
270,000 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$592,200
+140,000 vol $4.23 each |
331,386 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$528,750
+125,000 vol $4.23 each |
291,424 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,438,200
+340,000 vol $4.23 each |
1,022,332 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$528,750
+125,000 vol $4.23 each |
291,422 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$54,024 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$31,028 | |
Filed 2018-05-29 Tx date 2018-05-24 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
FRIESEN, HENRY
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$4,791 vol $7.83 each |
$20,117 | |
Filed 2018-05-17 Tx date 2018-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$9,517 vol $7.88 each |
$24,843 | |
Filed 2017-11-14 Tx date 2017-09-13 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
STILLER, CALVIN R.
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Moore, Michael
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Kirkman, Robert Lawrence
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Beshar, Luke
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
FRIESEN, HENRY
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$1,847 vol $12.18 each |
$1,847 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$298,045
+24,390 vol $12.22 each |
166,422 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Uger, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$342,758
+28,049 vol $12.22 each |
191,386 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,222,000
+100,000 vol $12.22 each |
682,332 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Sievers, Eric L
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$342,758
+28,049 vol $12.22 each |
191,386 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Petrova, Penka
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$298,045
+24,390 vol $12.22 each |
166,424 | |
Filed 2017-08-31 Tx date 2017-08-28 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Sievers, Eric L
5 - Senior Officer of Issuer
Holder: Eric and Nicole Sievers (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$49,173
+10,640 vol $4.62 each |
52,884 | |
Filed 2017-08-21 Tx date 2017-08-17 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,760
+2,100 vol $5.60 each |
12,800 | |
Filed 2017-08-21 Tx date 2017-08-21 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,210
+2,200 vol $5.55 each |
15,000 | |
Filed 2017-08-18 Tx date 2017-08-16 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$22,464
+4,000 vol $5.62 each |
10,000 | |
Filed 2017-08-18 Tx date 2017-08-17 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Stiernholm, Bjorn Johan Niclas
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,955
+700 vol $5.65 each |
10,700 |